Cargando…
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
Drug-induced thrombotic microangiopathies present in similar fashion but have varied pathogenic mechanisms. Carfilzomib is an irreversible proteasome inhibitor. Since its initial approval as a single agent for the treatment of relapsed or refractory multiple myeloma in 2012, there have been increasi...
Autores principales: | Eigbire-Molen, Odianosen, Hermelin, Daniela, Blackall, Douglas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239517/ https://www.ncbi.nlm.nih.gov/pubmed/35837078 http://dx.doi.org/10.14740/jmc3932 |
Ejemplares similares
-
Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
por: Gosain, Rahul, et al.
Publicado: (2017) -
Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021) -
Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition
por: Catanese, Lorenzo, et al.
Publicado: (2023) -
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
por: Hobeika, Liliane, et al.
Publicado: (2014) -
Thrombotic microangiopathy during carfilzomib use: case series in Singapore
por: Chen, Y, et al.
Publicado: (2016)